DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212,572 | -32.3% | 10,304 | -3.1% | 0.01% | -30.0% |
| Q2 2023 | $313,957 | +20.2% | 10,639 | -6.2% | 0.02% | +25.0% |
| Q1 2023 | $261,251 | +27.9% | 11,339 | +54.4% | 0.02% | +45.5% |
| Q4 2022 | $204,209 | -52.4% | 7,343 | -23.6% | 0.01% | 0.0% |
| Q4 2021 | $429,000 | +41.6% | 9,610 | +59.8% | 0.01% | +37.5% |
| Q3 2021 | $303,000 | -22.5% | 6,012 | +20.7% | 0.01% | -33.3% |
| Q2 2021 | $391,000 | +58.3% | 4,983 | +68.9% | 0.01% | +100.0% |
| Q4 2020 | $247,000 | -24.2% | 2,950 | -67.6% | 0.01% | -62.5% |
| Q3 2020 | $326,000 | +23.5% | 9,100 | -16.6% | 0.02% | +6.7% |
| Q2 2020 | $264,000 | +169.4% | 10,909 | +158.0% | 0.02% | +150.0% |
| Q1 2019 | $98,000 | +139.0% | 4,229 | +113.9% | 0.01% | +100.0% |
| Q4 2018 | $41,000 | – | 1,977 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |